CY1119657T1 - Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας - Google Patents
Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτηταςInfo
- Publication number
- CY1119657T1 CY1119657T1 CY20171101223T CY171101223T CY1119657T1 CY 1119657 T1 CY1119657 T1 CY 1119657T1 CY 20171101223 T CY20171101223 T CY 20171101223T CY 171101223 T CY171101223 T CY 171101223T CY 1119657 T1 CY1119657 T1 CY 1119657T1
- Authority
- CY
- Cyprus
- Prior art keywords
- genetically modified
- human
- mathes
- modified major
- compatibility complex
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 210000002257 embryonic structure Anatomy 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552587P | 2011-10-28 | 2011-10-28 | |
| US201161552582P | 2011-10-28 | 2011-10-28 | |
| US201261700908P | 2012-09-14 | 2012-09-14 | |
| PCT/US2012/062042 WO2013063346A1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified major histocompatibility complex mice |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119657T1 true CY1119657T1 (el) | 2018-04-04 |
Family
ID=47178940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101223T CY1119657T1 (el) | 2011-10-28 | 2017-11-22 | Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας |
| CY20191100840T CY1121869T1 (el) | 2011-10-28 | 2019-08-07 | Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100840T CY1121869T1 (el) | 2011-10-28 | 2019-08-07 | Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας |
Country Status (27)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013063556A1 (en) | 2011-10-28 | 2013-05-02 | Regeneron Pharmaceuticals, Inc. | Humanized il-6 and il-6 receptor |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| SMT201900429T1 (it) | 2013-02-20 | 2019-09-09 | Regeneron Pharma | Topi esprimenti co-recettori umanizzati linfociti t |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| EP2958937B1 (en) * | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| WO2014164640A1 (en) * | 2013-03-11 | 2014-10-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules |
| DK4269430T3 (da) | 2013-09-23 | 2025-08-18 | Regeneron Pharma | Ikke-menneskelige dyr, der har et humaniseret signalregulerende proteingen |
| SI3138397T1 (sl) | 2013-10-15 | 2019-04-30 | Regeneron Pharmaceuticals, Inc. | Humanizirane živali IL-15 |
| CN105578876B (zh) * | 2013-10-18 | 2018-07-13 | 大鹏药品工业株式会社 | 制备表达hlai类的非人动物的方法 |
| MY183188A (en) | 2013-11-19 | 2021-02-18 | Regeneron Pharma | Non-human animals having a humanized b-cell activating factor gene |
| KR102173297B1 (ko) | 2013-11-19 | 2020-11-03 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 증식-유도 리간드 유전자를 가지고 있는 비-인간 동물 |
| ES2794942T3 (es) | 2014-04-08 | 2020-11-19 | Regeneron Pharma | Animales no humanos que tienen receptores Fc-gamma humanizados |
| JP6598798B2 (ja) | 2014-05-05 | 2019-10-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｃ５およびｃ３動物 |
| NO2785538T3 (cg-RX-API-DMAC7.html) | 2014-05-07 | 2018-08-04 | ||
| WO2015196051A1 (en) | 2014-06-19 | 2015-12-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| JP2017529841A (ja) | 2014-09-19 | 2017-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | キメラ抗原受容体 |
| RS63410B1 (sr) | 2014-11-24 | 2022-08-31 | Regeneron Pharma | Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks |
| BR112017010490A2 (pt) | 2014-12-05 | 2018-04-03 | Regeneron Pharma | roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. |
| LT3230320T (lt) * | 2014-12-09 | 2021-01-11 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną |
| CN116059378A (zh) | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| DK3280257T3 (da) | 2015-04-06 | 2023-09-04 | Regeneron Pharma | Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr |
| PT3282835T (pt) * | 2015-04-13 | 2023-07-25 | Univ Yale | Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos |
| LT3376857T (lt) | 2015-11-20 | 2021-06-25 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| EP3462853B1 (en) | 2016-06-03 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Rodents expressing exogenous terminal deoxynucleotidyltransferase |
| CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| KR102696334B1 (ko) | 2017-09-29 | 2024-08-21 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 C1q 복합체를 발현하는 비인간 동물 |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| AU2018375796B2 (en) | 2017-11-30 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TRKB locus |
| HUE070158T2 (hu) * | 2018-03-24 | 2025-05-28 | Regeneron Pharma | Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk |
| AU2019242586B2 (en) | 2018-03-26 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| PL3823443T3 (pl) | 2018-07-16 | 2024-09-23 | Regeneron Pharmaceuticals, Inc. | Modele gryzoni z chorobą ditra i ich zastosowania |
| US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
| BR112021018788A2 (pt) * | 2019-03-25 | 2021-11-23 | Xenotherapeutics Corp | Células, tecidos e órgãos personalizados para transplante de um doador (não humano) humanizado, indivi-dualizado, designado livre de patógenos e métodos e produtos relacionados aos mesmos |
| IL286905B2 (en) | 2019-04-04 | 2024-06-01 | Regeneron Pharma | Non-human animals containing the human coagulation factor 12 locus |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| SG11202111256XA (en) | 2019-06-07 | 2021-11-29 | Regeneron Pharma | Non-human animals comprising a humanized albumin locus |
| EP4087392A4 (en) * | 2020-01-10 | 2024-02-21 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC MHC PROTEIN COMPLEX |
| WO2022133155A1 (en) * | 2020-12-16 | 2022-06-23 | Xenotherapeutics, Inc. | Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs |
| CN116848254A (zh) | 2020-12-16 | 2023-10-03 | 瑞泽恩制药公司 | 表达人源化Fcα受体的小鼠 |
| AU2022249328A1 (en) | 2021-03-31 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire |
| EP4536836A1 (en) | 2022-06-07 | 2025-04-16 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| KR20250035053A (ko) | 2022-06-07 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도 |
| KR20250077529A (ko) | 2022-09-22 | 2025-05-30 | 리제너론 파아마슈티컬스, 인크. | 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스 |
| WO2024159071A1 (en) | 2023-01-27 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Modified rhabdovirus glycoproteins and uses thereof |
| TW202520975A (zh) * | 2023-08-09 | 2025-06-01 | 英商劍橋企業有限公司 | 基因改造之囓齒動物及囓齒動物細胞以及其等用途 |
| WO2025064470A1 (en) | 2023-09-19 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Viral peptides and uses thereof |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| WO2025136809A2 (en) | 2023-12-19 | 2025-06-26 | Regeneron Pharmaceuticals, Inc. | Foxp3 peptides and uses thereof |
| WO2025178991A1 (en) | 2024-02-21 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Splicing factor gene mutation-associated neoantigenic peptides and uses thereof |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| AU633958B2 (en) | 1989-07-25 | 1993-02-11 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| WO1993005817A1 (en) | 1991-09-19 | 1993-04-01 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | Transgenic non-human animals having targeted lymphocyte transduction genes. |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| EP0910409A4 (en) | 1996-03-05 | 2003-03-19 | Scripps Research Inst | RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| AU752590B2 (en) * | 1998-02-17 | 2002-09-26 | Ortho-Mcneil Pharmaceutical, Inc. | H2-O modified transgenic animals |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| WO2001027291A1 (en) * | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JPWO2002047474A1 (ja) | 2000-12-13 | 2004-04-15 | 住友製薬株式会社 | Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用 |
| US20030093818A1 (en) | 2000-12-19 | 2003-05-15 | Belmont Heather J. | Transgenic animals comprising a humanized immune system |
| FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| JP4857450B2 (ja) | 2004-03-09 | 2012-01-18 | 財団法人名古屋産業科学研究所 | ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物 |
| PL1802193T3 (pl) | 2004-10-19 | 2014-09-30 | Regeneron Pharma | Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej |
| JP4830139B2 (ja) * | 2006-03-10 | 2011-12-07 | 学校法人明治大学 | クローン胚の作製方法 |
| NZ547859A (en) * | 2006-06-09 | 2009-05-31 | Dec Int Nz Ltd | Treatment method and composition for mastitis |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| EP1878342A1 (en) * | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| CA2685015A1 (en) * | 2007-04-23 | 2008-11-06 | Schering Corporation | Anti-mdl-1 antibodies |
| EP2262898B1 (en) | 2008-03-07 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Es cell-derived mice from diploid host embryo injection |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| EP2153845A1 (en) * | 2008-08-13 | 2010-02-17 | Julius-Maximilians-Universität Würzburg | Endoglin peptides, vaccines and methods for preparing the same |
| EP2517556B2 (en) * | 2009-07-08 | 2023-03-22 | Kymab Limited | Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains |
| WO2012039779A1 (en) | 2010-09-24 | 2012-03-29 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| SMT201900429T1 (it) | 2013-02-20 | 2019-09-09 | Regeneron Pharma | Topi esprimenti co-recettori umanizzati linfociti t |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| EP2958937B1 (en) | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| CN105683383B (zh) * | 2013-06-03 | 2020-08-21 | 赛拉福柯蒂斯公司 | 含有I型MHC、II型MHC或β2微球蛋白上游启动子序列的慢病毒载体 |
| CN105578876B (zh) * | 2013-10-18 | 2018-07-13 | 大鹏药品工业株式会社 | 制备表达hlai类的非人动物的方法 |
| DK3280257T3 (da) | 2015-04-06 | 2023-09-04 | Regeneron Pharma | Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr |
-
2012
- 2012-10-26 LT LTEP17184955.7T patent/LT3262932T/lt unknown
- 2012-10-26 CA CA3074400A patent/CA3074400C/en active Active
- 2012-10-26 CN CN201280060540.8A patent/CN104039132B9/zh active Active
- 2012-10-26 MX MX2020010763A patent/MX391222B/es unknown
- 2012-10-26 RS RS20190998A patent/RS59082B1/sr unknown
- 2012-10-26 US US13/661,159 patent/US9615550B2/en active Active
- 2012-10-26 EP EP12787255.4A patent/EP2770821B1/en active Active
- 2012-10-26 RS RS20171195A patent/RS56656B1/sr unknown
- 2012-10-26 MX MX2014004895A patent/MX355725B/es active IP Right Grant
- 2012-10-26 SI SI201231650T patent/SI3262932T1/sl unknown
- 2012-10-26 HR HRP20171761TT patent/HRP20171761T1/hr unknown
- 2012-10-26 KR KR1020147014476A patent/KR101921126B1/ko active Active
- 2012-10-26 SI SI201231136T patent/SI2770821T1/en unknown
- 2012-10-26 EP EP19167619.6A patent/EP3563680B1/en active Active
- 2012-10-26 PT PT127872554T patent/PT2770821T/pt unknown
- 2012-10-26 AU AU2012324016A patent/AU2012324016C1/en active Active
- 2012-10-26 KR KR1020187033187A patent/KR102074145B1/ko active Active
- 2012-10-26 CN CN202110831383.7A patent/CN113564188B/zh active Active
- 2012-10-26 ES ES12787255.4T patent/ES2651517T3/es active Active
- 2012-10-26 SM SM20170576T patent/SMT201700576T1/it unknown
- 2012-10-26 ES ES19167619T patent/ES2962287T3/es active Active
- 2012-10-26 KR KR1020207002887A patent/KR102295746B1/ko active Active
- 2012-10-26 WO PCT/US2012/062042 patent/WO2013063346A1/en not_active Ceased
- 2012-10-26 MX MX2017013466A patent/MX376167B/es unknown
- 2012-10-26 PT PT17184955T patent/PT3262932T/pt unknown
- 2012-10-26 DK DK17184955.7T patent/DK3262932T3/da active
- 2012-10-26 NZ NZ734532A patent/NZ734532A/en unknown
- 2012-10-26 LT LTEP12787255.4T patent/LT2770821T/lt unknown
- 2012-10-26 HU HUE17184955A patent/HUE045879T2/hu unknown
- 2012-10-26 PL PL12787255T patent/PL2770821T3/pl unknown
- 2012-10-26 HU HUE12787255A patent/HUE035652T2/en unknown
- 2012-10-26 EP EP17184955.7A patent/EP3262932B1/en active Active
- 2012-10-26 SM SM20190478T patent/SMT201900478T1/it unknown
- 2012-10-26 ES ES17184955T patent/ES2741649T3/es active Active
- 2012-10-26 SG SG11201400933VA patent/SG11201400933VA/en unknown
- 2012-10-26 CA CA2850387A patent/CA2850387A1/en active Pending
- 2012-10-26 PL PL17184955T patent/PL3262932T3/pl unknown
- 2012-10-26 SG SG10201603188SA patent/SG10201603188SA/en unknown
- 2012-10-26 MY MYPI2017703836A patent/MY178723A/en unknown
- 2012-10-26 MY MYPI2014000784A patent/MY164836A/en unknown
- 2012-10-26 DK DK12787255.4T patent/DK2770821T3/da active
- 2012-10-26 EP EP23193595.8A patent/EP4311833A3/en active Pending
- 2012-10-26 BR BR112014009259-1A patent/BR112014009259A2/pt not_active Application Discontinuation
- 2012-10-26 JP JP2014539029A patent/JP6154391B2/ja active Active
- 2012-10-26 CN CN201710347715.8A patent/CN107254480B/zh active Active
-
2014
- 2014-04-13 IL IL232097A patent/IL232097A/en active IP Right Grant
- 2014-04-25 ZA ZA2014/03085A patent/ZA201403085B/en unknown
-
2016
- 2016-04-27 AU AU2016202688A patent/AU2016202688B2/en active Active
-
2017
- 2017-02-22 US US15/439,828 patent/US10869466B2/en active Active
- 2017-04-30 IL IL252022A patent/IL252022A0/en active IP Right Grant
- 2017-06-01 JP JP2017109327A patent/JP6574457B2/ja active Active
- 2017-11-22 CY CY20171101223T patent/CY1119657T1/el unknown
- 2017-12-22 AU AU2017279797A patent/AU2017279797C1/en active Active
-
2018
- 2018-06-29 HK HK18108466.8A patent/HK1249712B/en unknown
- 2018-08-20 IL IL26123918A patent/IL261239B/en active IP Right Grant
-
2019
- 2019-02-06 JP JP2019019707A patent/JP6866409B2/ja active Active
- 2019-08-06 HR HRP20191420 patent/HRP20191420T1/hr unknown
- 2019-08-07 CY CY20191100840T patent/CY1121869T1/el unknown
-
2020
- 2020-05-07 JP JP2020081774A patent/JP2020146041A/ja not_active Withdrawn
- 2020-08-12 US US16/991,283 patent/US20200375160A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119657T1 (el) | Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας | |
| CY1122700T1 (el) | Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (μηc) ii | |
| CY1121223T1 (el) | Ποντικοι οι οποιοι εκφραζουν ανθρωποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας | |
| CY1123831T1 (el) | Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων | |
| CY1121979T1 (el) | Ποντικια που εκφραζουν ανθρωποποιημενους τ-λεμφοκυτταρικους συνυποδοχεις | |
| CY1122036T1 (el) | Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα | |
| FIC20250010I1 (fi) | Autologiset anti-CD19-transduktoidut CD3+-solut (breksukabtageeniautoleuseeli) | |
| CY1121410T1 (el) | Μη-ανθρωπινα ζωα που εχουν ενα εξανθρωποποιημενο γονιδιο ρυθμιστικης πρωτεϊνης σηματος | |
| CY1121405T1 (el) | Εξανθρωποποιημενα il-15 ζωα | |
| MX391051B (es) | Anticuerpos anti-cd47 y usos de los mismos. | |
| MX2017006802A (es) | Animales no humanos que expresan el complejo cd3 humanizado. | |
| MX364714B (es) | Animales no humanos geneticamente modificados y metodos de uso de los mismos. | |
| CY1120390T1 (el) | Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων | |
| EA201391234A1 (ru) | Генетически модифицированные животные и способы их получения | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| MX385585B (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| MX380302B (es) | Anticuerpos anti-phf-tau y sus usos. | |
| MX2017001694A (es) | Ligadores de nucleotidos modificados. | |
| CY1123046T1 (el) | Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ | |
| IL243127B (en) | Humanized or chimeric cd3 antibodies | |
| EA201590173A1 (ru) | Иммуноконъюгаты, содержащие антитела к cd22 | |
| MX2019000641A (es) | Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso. | |
| MX2021003654A (es) | Metodo para seleccionar neoepitopes. | |
| BR112017001550A2 (pt) | enxerto de tecido | |
| EP4249507A3 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |